CannGros ApS - matokeo ya utafutaji kwa

Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

onbevzi

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastické činidlá - onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. onbevzi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. Ďalšie informácie o stave receptora ľudského epidermálneho rastového faktora 2 (her2) nájdete v časti 5. onbevzi in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with onbevzi in combination with capecitabine. Ďalšie informácie o stave her2 nájdete v časti 5. onbevzi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. onbevzi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. onbevzi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. onbevzi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. onbevzi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

omeprazole zentiva

zentiva, k.s., Česká republika - omeprazol - 09 - antacida (vrÁtane antiulcerosnych lieČiv)

Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

omeprazole olikla 40 mg prášok na infúzny roztok

olikla s.r.o., Česká republika - omeprazol - 09 - antacida (vrÁtane antiulcerosnych lieČiv)

Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

letifend

leti pharma, s.l.u. - recombinant protein q from leishmania infantum mon-1 - inaktivované bakteriálne vakcíny (vrátane mycoplasma, toxoid a chlamydia) - psy - na aktívnu imunizáciu psov od 6 mesiacov, aby sa znížilo riziko vzniku klinického prípadu leishmaniózy.

Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

cement kostný artrocare